Skip to main content
. 2020 May 30;12(6):501. doi: 10.3390/pharmaceutics12060501

Figure 4.

Figure 4

Comparison of the design of eCAP WLBU2 to that of recent AMPs with high potency. Both SAAP-148 and ZY4 are based on the modification of a cathelicidin with incorporation of Trp (W) and reduction in the number of amino acid residues to form a more ideal cationic amphipathic structure. ZY4 has a disulfide bridge indicated by a broken line in red.